A Randomized, Double-Blind, Placebo Controlled Three-Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX 4 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts, and Bioavailability of Oral MRX-4 Versus Intravenous Administration
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Contezolid-acefosamil (Primary) ; Contezolid-acefosamil (Primary)
- Indications Gram-positive infections
- Focus Adverse reactions
- Sponsors MicuRx Pharmaceuticals
- 20 Mar 2018 Status changed from recruiting to completed.
- 06 Dec 2016 New trial record